# Effectiveness of Dapagliflozin for Weight Loss

> **NCT03968224** · PHASE2,PHASE3 · COMPLETED · sponsor: **Centro Medico Nacional Siglo XXI IMSS** · enrollment: 160 (actual)

## Conditions studied

- PreDiabetes
- Obesity, Morbid
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Dapagliflozin/Metformin
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT03968224
- **Lead sponsor:** Centro Medico Nacional Siglo XXI IMSS
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-04
- **Primary completion:** 2024-07-31
- **Final completion:** 2024-07-31
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2025-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03968224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03968224, "Effectiveness of Dapagliflozin for Weight Loss". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT03968224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*